Global Plasma Fractionation Market Future Trends - Business Overview, Recent Developments, Company Profile 2021
The Global Plasma Fractionation Market was worth USD 19.4 billion in 2016 and is projected to be growing at a CAGR of 7.2%, to touch USD 27.46 billion by 2021. Blood fractionation is the process of fractionating whole blood or segregating it into its constituent parts.
Whole blood consists of red cells, white cells, and platelets, suspended in plasma, which constitutes about 55% of blood by volume.
Browse Market data tables and in-depth TOC of the Global Plasma Fractionation Market to 2021 at www.marketdataforecast.com/market-…tion-market-2837/
Plasma is the liquid portion of blood.
Plasma helps in maintaining blood pressure and body temperature regulation.
The growth of the Global Plasma Fractionation Market is mainly driven by factors such as increasing incidence of immune and bleeding disorders, growing incidence of Alpha-1 Antitrypsin deficiency and the rising use of immunoglobulins, which are basically antibodies. Further, growing aging population with related blood related ailments is set to further drive market growth.
However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the major constraints of market growth.
The Global Plasma Fractionation Market is segmented on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors.
Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.
The market has been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. As of 2016, North America leads the market, with the U.S.
accounting for a major share. North America’s lead is justified by the presence of high number of registered haemophilic patients and increasing use of immunoglobulins in neurologic disorders. Europe comes in second in terms of market share owing to the rising awareness about blood related disorders and the swift availability of treatment in terms of plasma fractionation.
However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period majorly because of the presence of larger elderly population numbers leading to higher incidence of blood disorders.
The major players in the Plasma Fractionation market are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc.
(China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
Category: Market Research Publishers and RetailersCompany about: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information:Make an Inquiry about this report HERE!